title: Cardiac troponin T as a marker of myocardial damage caused by antineoplastic drugs in rabbits.
abstract: Anthracycline derivatives are among the most effective antineoplastic drugs but their therapeutic use is limited by their adverse effects. The cardiac side-effects of antineoplastic drugs were investigated in rabbits in vivo from the viewpoint of release of cardiac troponin T (cTnT) measured by Elecsys Troponin T STAT immunoassay (Boehringer Mannheim, Germany). No increase in cTnT was found following administration of a single dose of daunorubicin (3 mg/kg i.v., n = 4). During development of daunorubicin-induced cardiomyopathy (daunorubicin 3 mg/kg i.v., once a week; maximum nine administrations, n = 7), the levels of cTnT were within the physiological range (i.e. cTnT <0.1 microg/l) at the beginning of the experiment and before and after the 5th administration, but the pathological values of cTnT after the 8th administration in 43% animals (0.22+/-0.08 microg/l) correlated with their premature death. In the control group, the levels of cTnT were always lower than 0.1 microg/l during the experiment. Following administration of a new antineoplastic drug - Oracin [6-[2-(2-hydroxyethyl) aminoethyl]-5,11-dioxo-5,6-dihydro-11H-indeno [1,2-c]-isoquinoline hydrochloride, 10 mg/kg i.v., once weekly, ten administrations, n = 7], there was no increase in cTnT levels. These findings correlated with the PEP: LVET index, histological examination and no animal succumbing to premature death. It is possible to conclude that cTnT is a useful marker for the prediction of experimentally induced anthracycline cardiomyopathy and for the evaluation of cardiotoxic (and, possibly, cardioprotective) effects of new drugs in rabbits.
authors.affiliation: Department of Physiology, Charles University Faculty of Medicine in Hradec Králové, Czech Republic. adamcova@lfhk.cuni.cz
authors.forename: M
authors.initials: M
authors.lastname: Adamcová
authors.forename: V
authors.initials: V
authors.lastname: Gersl
authors.forename: R
authors.initials: R
authors.lastname: Hrdina
authors.forename: M
authors.initials: M
authors.lastname: Melka
authors.forename: Y
authors.initials: Y
authors.lastname: Mazurová
authors.forename: J
authors.initials: J
authors.lastname: Vávrová
authors.forename: V
authors.initials: V
authors.lastname: Palicka
authors.forename: Z
authors.initials: Z
authors.lastname: Kokstein
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D015415:Biomarkers / Q000032:analysis*; D009202:Cardiomyopathies / Q000139:chemically induced* / Q000378:metabolism*; D003630:Daunorubicin / Q000009:adverse effects*; D004334:Drug Administration Schedule; D004983:Ethanolamines / Q000009:adverse effects*; D007262:Infusions, Intravenous; D007546:Isoquinolines / Q000009:adverse effects*; D008297:Male; D009206:Myocardium / Q000378:metabolism*; D011817:Rabbits; D020107:Troponin T / Q000378:metabolism*
chemical_list: D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D015415:Biomarkers; D004983:Ethanolamines; D007546:Isoquinolines; D020107:Troponin T; C103439:oracine; D003630:Daunorubicin